A testosterone blood test can feel like a simple answer: low number, low desire, treatment.
For women after menopause, the guidance is more careful than that.
International Society for the Study of Women's Sexual Health guidance supports systemic testosterone only after a careful hypoactive sexual desire disorder assessment in women. Testing is used for baseline and follow-up monitoring. [1]
The test is useful.
It is not the diagnosis.
Can a testosterone blood test for women after menopause diagnose low desire?
The global consensus statement is narrow. The only evidence-based use it supports is testosterone treatment for postmenopausal women with hypoactive sexual desire disorder after a full assessment. [2]
That assessment matters because low desire has many causes. Pain with sex, vaginal dryness, poor sleep, depression, anxiety, stress, medications, thyroid disease, alcohol, chronic illness, trauma, relationship strain, and hot flashes can all play a role.
A blood level cannot sort that out by itself.
The Endocrine Society guideline makes the same broad point: it recommends against diagnosing an androgen-deficiency syndrome in healthy women because the syndrome is not well defined and androgen levels do not reliably map to specific symptoms. It also recommends against general testosterone use for sexual dysfunction other than hypoactive sexual desire disorder, cognition, cardiovascular health, metabolic health, bone health, or general well-being. [6]
That is why "low testosterone" is the wrong first label for most women. The better first label is the symptom pattern: hypoactive sexual desire disorder, genitourinary syndrome of menopause, pain, mood, sleep, medication effect, relationship context, thyroid disease, anemia, or something else.
What the blood test can and cannot do
| Claim about the test | Accurate use | Problem use |
|---|---|---|
| "It diagnoses low desire." | No. Hypoactive sexual desire disorder is diagnosed clinically after a biopsychosocial assessment. | A number is used to skip the sexual-health evaluation. |
| "It confirms testosterone will help." | No. It can document baseline context before a monitored trial. | A low-normal result is treated like a direct treatment predictor. |
| "It sets the dose target." | No. The goal is symptom benefit without supraphysiologic exposure. | Dose is raised to chase a higher number. |
| "It is still useful." | Yes. It helps exclude unexpectedly high baseline levels and monitor overuse. | Testing is sold as a direct-to-treatment shortcut. |
| "Any assay is fine." | Not exactly. Female-range levels are technically harder to measure. | A weak assay result is overinterpreted as a diagnosis. |
International Society for the Study of Women's Sexual Health states directly that total testosterone should not be used to diagnose hypoactive sexual desire disorder, but should be used as a baseline for monitoring. [1]
The lab method matters
Women often have testosterone concentrations near the low end of what many routine assays can measure well. The International Society for the Study of Women's Sexual Health guideline notes that direct assays for total and free testosterone are highly unreliable in the female range. It says total testosterone can be measured with better accuracy and reproducibility using liquid chromatography or gas chromatography with tandem mass spectrometry methods, although even those methods are not internationally standardized. [1]
That does not mean every result is useless. It means a small difference between "low," "normal," and "borderline" should not be treated like a diagnosis.
A careful clinician asks what assay was used, whether the result fits the symptoms, whether the baseline value is unexpectedly high, and how the level will be used to prevent excessive dosing if treatment starts.
Why clinicians still order the test
Testing can help before and during therapy. A baseline level may show unexpectedly high testosterone or another reason to pause. Follow-up levels help avoid doses that push levels too high.
International Society for the Study of Women's Sexual Health guidance says levels should be monitored so dosing does not push a woman above the normal premenopausal female range. [1]
Another International Society for the Study of Women's Sexual Health publication carries the same frame: systemic testosterone is monitored hypoactive sexual desire disorder therapy, not a lab-value shortcut. [4]
That is a safety use, not a marketing use. A clinic should not use a borderline or low-normal number to promise better mood, energy, body composition, or anti-aging outcomes.
The evidence base is strongest for low desire disorder
A systematic review and meta-analysis of randomized trials found that testosterone can improve sexual-function outcomes in postmenopausal women. It retrieved 46 reports from 36 randomized trials with 8,480 participants and found improvements including 0.85 more satisfactory sexual events on average versus placebo or comparator. Acne and unwanted hair growth were key side effects to monitor, and oral testosterone worsened lipid measures compared with non-oral routes. [3]
That supports a specific clinical conversation. It does not turn testosterone into a broad menopause treatment.
A 2025 position statement on androgen therapy in midlife and older women reaches the same operational boundary: testosterone therapy for postmenopausal women should be limited to hypoactive sexual desire disorder confirmed through formal biopsychosocial evaluation; routine serum measurements are not recommended for diagnosis; baseline levels should be checked before therapy; monitoring should occur within 3 to 6 weeks; transdermal formulations are preferred; and pellets plus compounded "bioidentical" testosterone are not recommended because of supraphysiologic dosing risk and insufficient evidence. [5]
What a lab conversation should include
| Topic | Why it matters |
|---|---|
| Symptom target | Treatment should name hypoactive sexual desire disorder, not vague "optimization." |
| Distress | hypoactive sexual desire disorder includes distress, not just a lower libido than before. |
| Pain and genitourinary syndrome of menopause | Painful sex can suppress desire and needs separate treatment. |
| Medication review | Antidepressants, opioids, alcohol, and other exposures can affect desire. |
| Baseline total testosterone | Useful for context and later safety monitoring, not diagnosis by itself. |
| sex hormone-binding globulin | High sex hormone-binding globulin can reduce likelihood of benefit; oral estrogen, thyroid replacement, and thyroid disease can affect it. [1] |
| Liver and lipid context | International Society for the Study of Women's Sexual Health recommends liver function and fasting lipid profile before treatment. [1] |
| Follow-up level | Helps avoid supraphysiologic dosing. |
| Side effects | Acne, hair growth, scalp shedding, voice change, and clitoral symptoms need review. |
A practical monitoring timeline
| Timing | What should happen | Why it matters |
|---|---|---|
| Before treatment | Confirm hypoactive sexual desire disorder after a biopsychosocial assessment; check total testosterone, sex hormone-binding globulin, liver function, and fasting lipids when considering therapy. [1] | Establish diagnosis and avoid starting when baseline risk or levels argue against it. |
| 3 to 6 weeks after start | Recheck total testosterone. [1] | Titrate safely and make sure dosing is not excessive. |
| After dose increase | Repeat total testosterone within about 6 weeks. [1] | Dose changes can overshoot even if symptoms have not improved yet. |
| If level is supraphysiologic | Reduce dose and repeat testing after 2 to 3 weeks. [1] | Side effects can occur even before they are obvious. |
| Once stable | Monitor testosterone about every 4 to 6 months, plus side effects and clinical benefit. [1] | Screens for overuse and dose creep. |
| By 6 months | Stop or reassess if there is no clinically meaningful improvement. [1] | Lack of benefit should not lead to indefinite escalation. |
The goal of testing is not to find a heroic number. The goal is to keep exposure in a female physiologic range while asking whether desire and distress actually improve.
Who it fits, and who should avoid a shortcut
Testosterone testing fits a postmenopausal woman being evaluated for persistent low sexual desire that causes distress, after pain, genitourinary syndrome of menopause, sleep, mood, medications, relationship context, and medical causes have been reviewed. It also fits someone already using testosterone who needs safety monitoring, side-effect review, and dose correction.
It is a poor fit when the main goal is fatigue, weight loss, brain fog, mood, muscle, confidence, or anti-aging. It is also a poor fit when a clinic treats a direct-to-consumer lab result as a prescription, skips hypoactive sexual desire disorder assessment, uses pellets as routine, uses unclear compounded dosing, or escalates dose because the number is not "optimized."
Red flags in testosterone testing
Red flags include using a "low" lab result to bypass hypoactive sexual desire disorder assessment, escalating dose to chase energy or weight-loss claims, levels above the female physiologic range, acne or unwanted hair growth after starting, voice change, clitoral change, scalp shedding, abnormal lipids, liver disease, hormone-sensitive cancer history, pregnancy possibility, or a product with unclear dose.
Testing should slow those situations down, not justify them.
What to ask a clinician
Ask:
- What symptom are we treating, and does it meet hypoactive sexual desire disorder criteria after a biopsychosocial assessment?
- Is this test being used for baseline context, safety monitoring, or diagnosis?
- What assay is being used, and how reliable is it in the female range?
- Are sex hormone-binding globulin, liver function, fasting lipids, medication effects, genitourinary syndrome of menopause, pain, mood, sleep, and relationship context part of the review?
- What level would be considered too high for me?
- How often will levels and side effects be checked after starting or changing dose?
- What would make us stop even if the lab number looks acceptable?
Bottom line
Testosterone testing belongs in menopause and sexual-health content, but the answer should prevent a common shortcut.
The honest answer is: a testosterone blood test can support baseline and safety monitoring, but it does not diagnose hypoactive sexual desire disorder alone. Treatment decisions should start with a clinician-led sexual-health assessment, use the narrow evidence-supported indication, and monitor levels and side effects carefully.
How the assessment helps
A structured assessment can organize low-desire distress, pain or genitourinary syndrome of menopause symptoms, mood, sleep, medicines, relationship context, prior hormones, baseline testosterone, sex hormone-binding globulin, lipid and liver context, and side effects so a clinician can decide whether testing is useful for baseline monitoring, treatment safety, or another diagnosis. It is not a lab order or diagnosis by itself.
Related reading:
- Testosterone Therapy for Women After Menopause.
- Testosterone Monitoring for Women After Menopause.
- Testosterone for Brain Fog After Menopause.
- Testosterone for Fatigue After Menopause.
- Testosterone for Mood After Menopause.
References
[1] Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Climacteric. 2021;24(6):533-550. doi:10.1080/13697137.2021.1891773 https://pubmed.ncbi.nlm.nih.gov/33792440/
[2] Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric. 2019;22(5):429-434. doi:10.1080/13697137.2019.1637079 https://pubmed.ncbi.nlm.nih.gov/31474158/
[3] Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. doi:10.1016/s2213-8587(19)30189-5 https://pubmed.ncbi.nlm.nih.gov/31353194/
[4] Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18(5):849-867. doi:10.1016/j.jsxm.2020.10.009 https://pubmed.ncbi.nlm.nih.gov/33814355/
[5] Pilnik S, Belardo A, Marchesan LB, et al. Androgen therapy in midlife and older women: a position statement of the Latin American Association of Gynecological Endocrinology (ALEG). Climacteric. 2025;28(5):529-536. doi:10.1080/13697137.2025.2548805 https://pubmed.ncbi.nlm.nih.gov/40919649/
[6] Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-510. doi:10.1210/jc.2014-2260 https://pubmed.ncbi.nlm.nih.gov/25279570/